Will Anktiva Continue to Drive ImmunityBio's Top-Line Growth in 2026?

Core Insights - ImmunityBio (IBRX) had a successful year in 2025, with fourth-quarter and full-year results exceeding earnings and sales estimates, primarily driven by the performance of its product Anktiva [1][2] Financial Performance - IBRX reported net product revenues of $113 million for the full year 2025, reflecting a 700% increase year over year [2][7] - The growth in sales is attributed to repeat prescribing, indicating increased physician confidence in Anktiva's efficacy and safety [2][7] - Ongoing shortages of Bacillus Calmette-Guérin (BCG) have created treatment bottlenecks, further driving demand for Anktiva [2] Regulatory Developments - The company is expanding Anktiva's global regulatory presence, having secured approvals in the European Union and Saudi Arabia for the BCG-unresponsive NMIBC indication [3] - These international approvals are expected to enhance ImmunityBio's marketing efforts in non-U.S. territories, potentially catalyzing revenue growth [3] Competitive Landscape - ImmunityBio faces significant competition from established pharmaceutical companies such as Merck, Bristol Myers, and Roche, which have well-established immunotherapies in the oncology market [4][5] - These competitors possess greater financial resources, extensive commercial infrastructure, and strong relationships with healthcare providers, making market entry challenging for newer companies like ImmunityBio [5] Valuation and Market Performance - IBRX shares have outperformed the industry year to date, indicating positive market sentiment [6] - The stock is currently trading at a premium, with a price-to-sales (P/S) ratio of 33.86, significantly above the industry average of 2.00 [8]